AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines

AbbVie files fast-acting Botox successor in US

AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with a short-acting successor to its blockbuster Botox brand.

AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines

–TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effect of 2-3 weeks.

New Short-Term Botox-Like Treatment Moves Closer to FDA Review

The neurotoxin is characterized by a rapid onset of action as early as eight hours after administration and a shorter duration of effect of two to three weeks. AbbVie announced submission of a Biologics License Application to the US Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe glabellar lines. TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid …

AbbVie Files BLA for TrenibotE in Glabellar Lines

AbbVie seeks FDA approval for TrenibotE, a first-in-class botulinum toxin offering fast onset and short duration for glabellar lines.